Marie Migaud

I am a French-trained Chemist/Chemical Engineer with a PhD in organic synthesis from Michigan State University, postdoctoral training at the University of Bath and Oxford. My first independent academic position was at Queen’s University Belfast (Chemistry) in 2000. I was appointed first in faculty of science and engineering, then requested a joint appointment with the Center for Cell Biology and Cancer Research, and ultimately moved to the School of Pharmacy to fully exploit the collaborative network that my moving within the institution had allowed me to create. In 2016, I left my permanent UK academic position to join the Mitchell Cancer Institute at the University of South Alabama, after a sabbatical year in the department of Biochemistry at the Carver College of Medicine in Iowa. I seek to accelerate translational research programs through basic research in chemical biology and synthetic chemistry.
More specifically, I pursue chemical research on canonical and non-canonical nucleotides and dinucleotides in the context of cell bioenergetics and signaling. I direct biology-focused research projects supported by bespoke organic synthesis and knowledge-based metabolomics and RNA/DNAomics research. My laboratory’s activities focus on synthesizing nucleosidic isotopologues, nucleotide-derived cofactors, and catabolites and develop analytical platforms that help unravel their role in diseases linked to genomic and metabolic mitochondrial dysfunction. Key to our research efforts are novel synthetic methodologies of isotopically labeled and modified nucleos/tides using mechanochemistry to allow atom-efficient syntheses.

Carolyn Chapman

Carolyn Riley Chapman, PhD MS, joined the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) in October 2023 (mrctcenter.org). She is a Member of the Faculty of the Department of Medicine at Harvard Medical School and Lead Investigator in the Division of Global Health Equity (DGHE), Department of Medicine, Brigham and Women’s Hospital. Her work involves collaboration with diverse stakeholders to identify and address challenges in the research and development of genetic technologies and precision medicine, including cell and gene therapies. Since April 2023, Dr. Chapman serves as Co-Chair of the ELSI-Dedicated Genome Engineering Workgroup at the Center for Synthetic Regulatory Genomics (SyRGe), led by Dr. Jef Boeke, the Sol and Judith Bergstein Director of the Institute of Systems Genetics and Professor, Department of Biochemistry and Molecular Pharmacology, at NYU Grossman School of Medicine. Prior to joining the MRCT Center, Carolyn worked at NYU Grossman School of Medicine in various roles. Immediately before joining the MRCT Center, she was Faculty in the Center for Human Genetics and Genomics at NYU Grossman School of Medicine with a primary appointment as Research Assistant Professor in the Department of Population Health (Division of Medical Ethics). In the past, Carolyn has worked as an Associate/Lecturer and as Interim Associate Director for the Columbia Bioethics program; as a business strategy management consultant in the biopharmaceuticals industry at L.E.K. Consulting; at a start-up biopharmaceutical company, Aton Pharma; and as a freelance science/medical writer. Carolyn graduated summa cum laude from Dartmouth College with a BA in Biology. She has a PhD in Genetics from Harvard University and an MS in Bioethics from Columbia University. She completed a postdoctoral fellowship in medical ethics at NYU Grossman School of Medicine and a Graduate Certificate in Survey Research at UConn’s School of Public Policy.

Javin Oza

Engineering of cell-free systems, proteins & enzymes, and adopting bioengineering to the university classroom

Vaccines & Immunotherapies Online Symposium

The program features case studies in vaccine development for cancer and infectious diseases, offering insights into best practices and technological advancements. Engage in focused discussions and networking with thought leaders to understand immunotherapy innovations for cancer and autoimmune diseases. The event concludes with the release of the ‘Harnessing Vaccine Technologies & Immunotherapies with Best Practice Approaches’ report, summarizing key insights and emerging trends.

Oligo Chemistry and Therapeutics Online Symposium

Join global innovators at our symposium focused on oligo chemistry and therapeutics to explore advances in overcoming therapeutic challenges, optimising targeted delivery, and utilising analytical methods like liquid chromatography and mass spectrometry. Engage with experts on peptide-oligo conjugation, modification chemistry, and advanced synthesis technologies. Discuss clinical applications across disease areas and anticipate future uses. The event concludes with the ‘Harnessing Oligo Chemistry & Therapeutics Development with Best Practice Approaches’ report, summarising key insights and trends for effective utilisation.

Antibody Engineering with Novel Technologies Online Symposium

Join global innovators at our symposium on antibody engineering to explore cutting-edge topics such as best practice approaches, advanced therapeutics, and stability strategies. Engage with experts on AI applications and computational tools in antibody engineering. Discuss case studies on achieving stability through advanced methods. The event concludes with the ‘Harnessing Antibody Engineering with Best Practice Approaches’ report summarising key insights and trends for effective utilisation.

Julietta Sheng

Julietta Sheng is a Science Policy postdoctoral scholar at the Engineering Biology Research Consortium. Prior to EBRC, she was a Career Enhancement Core Scholar with the Innovation Center on Sex Differences in Medicine (ICON-X), a collaboration between Colorado State University and Massachusetts General Hospital – Boston. Through ICON-X, she partnered with bioengineers, clinicians, and academics to enhance evidence-based research, identify scientific challenges, and develop creative solutions.

Julietta recently earned her PhD in Biomedical Sciences – Neuroscience with Drs. Stuart Tobet and Robert J. Handa at Colorado State University with a focus on sex differences in the brain and body that lead to neuropsychiatric disorders.

Outside of work, Julietta likes to play kickball, read psychological thrillers, and go on long walks with her puppos.

Neil Dalvie

Neil Dalvie did his PhD in Chemical Engineering at MIT, studying therapeutic protein manufacturing. Now, he is a Schmidt Science Fellow in the Synthetic Biology Hive at Harvard Medical School. Neil researches large-scale bioprocessing for mineral processing and is interested in the ethics and regulation of environmental bioengineering.

Cameron Roots

Cameron is a recent graduate and postdoctoral fellow in the Barrick Lab at the University of Texas at Austin. He completed his B.S. in biochemistry and in molecular, cellular, and developmental biology at the University of Washington. Afterwards, he completed a postbactorial study at the National Institutes of Health as an IRTA fellow. His current research is at the intersection of synthetic and evolutionary biology, exploring how engineered systems are prone to mutation and developing tools to help researchers keep theirs stable. His prior policy activities include institutional policy initiatives within the UT Austin Interdisciplinary Life Sciences programs; independent study and programming as a Graduate Archer Fellow; and as an intern on biomanufacturing, biosecurity, and AIxBio federal policy.

Efrain Rodriguez-Ocasio

Efrain Rodriguez Ocasio is originally from Puerto Rico and graduated from the University of Puerto Rico-Mayagüez with a B.S. in Industrial Biotechnology. During his undergraduate studies, Efrain served as a trustee on the Governing Board of the University of Puerto Rico, which oversees the 11 campuses of Puerto Rico’s public University. He earned his Ph.D. in Chemical Engineering at Iowa State University, where he developed microbial platforms for plastic waste upcycling and earned the ISU Research Excellence Award. Efrain is currently a postdoctoral fellow at the Great Lakes Bioenergy Research Center and the University of Wisconsin-Madison. His research integrates metabolic and process modeling to identify new production targets for the decarbonization of the chemical industry and synthetic biology for industrial strain development.

Ross Klauer

Ross Klauer is a PhD candidate in Chemical and Biomolecular Engineering at the University of Delaware. He received his Bachelor of Science Degree in Chemical Engineering from Rose-Hulman Institute of Technology. Ross is co-advised by Dr. Mark Blenner and Dr. Kevin Solomon. Ross’ research focuses on elucidating the polyethylene deconstruction pathway in the digestive system of plastic-eating yellow mealworms. He is working to identify and engineer enzymes for polyethylene deconstruction. Outside of lab, Ross enjoys playing soccer and is a competitive cornhole player.